Evidence map›Paper›PMID 41929630›Full record

ArticleFrontiers in cell and developmental biology2026

Synergistic adverse prognosis of

Fujun Qu, Mingxu Hui, Fan Yang, Weiwei Wan, Nian Liu, Xianyi Wu, Yuchan He, Xiaotao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fujun Qu *Department of Hematology, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Mingxu Hui *Department of Radiation Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
Fan Yang *Department of Pathology, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Weiwei WanDepartment of Hematology, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Nian LiuHealth Management Center, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
Xianyi WuDepartment of Hematology, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Yuchan HeDepartment of Hematology, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
Xiaotao WangDepartment of Hematology, The First Affiliated Hospital of Guilin Medical University, Guilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Current prognostic stratification for acute myeloid leukemia (AML) patients primarily relies on international guidelines such as ELN 2022. However, these guidelines provide limited explicit guidance on how to comprehensively assess prognosis when patients harbor concurrent multiple gene mutations, potentially leading to inaccurate risk stratification. Methods: This retrospective cohort study enrolled 299 adult AML patients (median age: 53.5 years). Clinical features, mutation status of prognosis-related genes, complete remission (CR) rate after two induction courses, and overall survival (OS) were analyzed. Logistic regression and Cox proportional hazards models were employed. Results: In this study cohort, the incidence rates of Conclusion: The

Indexed as

acute myeloid leukemiaCEBPAco-mutationmolecular subtypeNRASprognosis

Identifiers

PMID41929630
PMCPMC13038965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.